Our latest pharma report - Companion Diagnostics: World Market Outlook 2011-2021 - offers a comprehensive view of the global companion diagnostics market. The report analyses recent trends in this market and anticipates the progression in the market over the next decade with global, regional and submarket forecasts. The report also reveals the market's strengths and weaknesses revealing areas that will experience growth and present new business opportunities. Visiongain analyses predict the global value of the companion diagnostics market in 2011 to be worth $1.57bn. A number of specialty drugs will be associated with a companion diagnostic test by 2021, increasing the global market for companion diagnostics.

Companion diagnostics are diagnostic tests that are linked to a particular drug/therapy. This is a small, emerging market at present, but one of the fastest growing segments in the IVD market. The concept of a drug-diagnostic combination is not new, but has only started to garner interest, with the move of healthcare towards personalised medicine. Companion diagnostics combined with targeted therapeutics are the tools for providing personalised treatment. This market has significant potential for growth with the increasing demand for safer, efficacious drugs.

Visiongain's research suggests that the world companion diagnostics market will benefit from developments in biomarker discovery and use in early stages of drug development. These biomarkers for disease can be developed into companion diagnostics for clinical use. Also benefiting the companion diagnostics market will be efforts on the part of the regulatory authorities to develop clearer regulatory guidelines for the co-development of companion diagnostics.

The Companion Diagnostics: World Market Outlook 2011-2021 report examines the scope of growth available in the companion diagnostics industry given the increasing cost of drug development, rising cost of healthcare, and the need for medicines which do not have adverse drug reactions.

The companion diagnostics market is the fastest growing segment in the IVD market. Visiongain predicts that this market will grow steadily to 2021. The future of the companion diagnostics market appears promising, with increases in the demand for high priced specialist therapies and the demand for safer, more-efficacious drugs.

How will the companion diagnostic market develop this decade? Which regions offer the most significant growth opportunities between 2011 and 2021? Which of the companion diagnostic submarkets are growing most strongly? Who are the leading companies in the companion diagnostics market? Which regions offer the most significant companion diagnostics market growth opportunities between 2011 and 2021?

Visiongain answers these critical questions and many more through the in-depth analyses that are presented in this report.

Detailed analysis of the global Companion Diagnostics Market

Companion Diagnostics: World Market Outlook 2011-2021 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are 50 tables and figures included, as well as two full interviews with relevant authorities. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.

Why you should buy Companion Diagnostics: World Market Outlook 2011-2021

In this report, you will receive the following benefits in particular:

• You will receive our assessment of the current market for companion diagnostics

• You will discover sales trends for the overall companion diagnostics market from 2011 to 2021 - seeing where commercial growth will occur

• You will discover sales trends for the main segment - theranostics - from 2011 to 2021 - with detailed discussions of market potential

• You will assess leading companies in the companion diagnostics market, providing products and services in the market

• You will see a compiled list of some theranostic kits and lab tests that are currently available in the market, and drug-diagnostic combinations in development by pharmaceutical and diagnostic companies

• You will examine the emerging business models for the development of companion diagnostics

• You will be able to investigate competition and opportunities influencing the companion diagnostics market from 2011 onwards

• You will see what will stimulate and restrain the companion diagnostics market from 2011

• You will discover the unmet needs in the market, driving the growth from 2011 onwards

• You will view expert opinion from our survey, including full interview transcripts.

You can obtain this report today

Anybody with an interest in the companion diagnostics and theranostics industry should gain valuable information and insight from this new study by Visiongain, which analyses one of the most important IVD industries. Success in the diagnostics and pharmaceutical market from 2011 to 2021 will be characterised by the launch of companion diagnostics products that will increase the efficacy and safety of the targeted drugs. You can find out about these developments and much more from this latest report from visiongain on Companion Diagnostics: World Market Outlook 2011-2021. You can stay ahead by ordering this report today.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6

Companies Listed

20/20 GeneSystems

A&G Pharmaceutical

Abbott Laboratories

Abbott Molecular

Abkine Pharmaceuticals

Advanced Cell Diagnostics

Aeterna Zentaris

Aetna

Agendia

Alacris Theranostics

Alere

Allegro Diagnostics

Almac Group

AltheaDx

Amgen

Amoy Diagnostics Company

Anthem

Ariad Pharmaceuticals

Array BioPharma

AssuerRx Health

AstraZeneca

Asuragen

Aureon Laboratories

AutoGenomics

Bayer Schering Pharma

Beckman Coulter

Biocartis

Biocrates Life Sciences

Biodesix

Biogen Idec

BioGenex Laboratories

BioMarin Pharmaceuticals

Biomarker Strategies

Biomedical Diagnostics (BMD)

bioMerieux

Biomonitor

Biotage

bioTheranostics

Boehringer Ingelheim

Brain Resource Company

Bristol-Myers Squibb

Cancer Research Technology Limited (CRT)

CancerGuide Diagnostics

Caprion Proteomics

Caris Life Sciences

Celera Corporation

Celgene Corporation

Centers for Medicare and Medicaid Services (CMS)

Cephalon

Cepheid

Cigna Corporation

Clavis Pharma

Clinical Reference Laboratory

Clovis Oncology

CompanDx

Crescendo Bioscience

Curidium Medica

Dako

Debiopharm Group

DiagnoCure

Dx assays

DxS

Eisai

Eli Lilly and Company

Endocyte

ERYtech Pharma

European Medicines Agency (EMA)

Exosome Diagnostics

Flagship Biosciences

Foundation Medicine

Genfit

GenMark Diagnostics

Genomic Health

Genzyme Genetics

GlaxoSmithKline

Hatteras Venture Partners

Health Net

HistologiX

Hoffmann-La Roche

Hologic

Humana

ImClone Systems

InDex Pharmaceuticals

Intersouth Partners

Inverness Medical Innovations

Invivoscribe Technologies

Ipsen

Ipsogen

Janssen Pharmaceutica

Johnson & Johnson

Kaiser Permanente

Kimball Genetics

Laboratory Corporation of America (LabCorp)

Laboratory for Personalized Molecular Medicine

Life Technologies Corporation

M.D. Anderson Cancer Center

MDxHealth

Merck KGaA

Merck Serono

MolecularMD

Monogram Biosciences

Myriad Genetics

Nanosphere

Neovacs

Newcastle University (UK)

Novartis Pharmaceuticals Corporation

Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

Oxford BioTherapeutics

Oxford Genome Sciences

Pfizer

Progenika Biopharma

Prometheus Laboratories

Psynova Neurotech

Qiagen

Quest Diagnostics

Quintiles Transnational Corporation

Randox Pharma Services

RiboMed Biotechnologies

Roche Molecular Systems

Rules-Based Medicine

Saladax Biomedical

Sanofi

Signal Genetics

Signature Diagnostics

Sirius Genomics

Skyline Diagnostics

Target Discovery

TcLand Expression

Telegraph Hill Partners

The Netherlands Cancer Institute (NKI)

Theranostics (NZ)

Theranostics Health

Third Wave Technologies

TIB MolBiol

Tragara Pharmaceuticals

Transgene

Transgenomic

TrimGen Corporation

Tufts Center for the Study of Drug Development

Unilabs

United HealthCare Services

US Food and Drug Administration (FDA)

US National Institutes of Health (NIH)

Ventana Medical Systems

Veridex

Weisenthal Cancer Group

WellPoint

Table of Contents

1. Executive Summary

1.1 Companion Diagnostics Market Review

1.2 Aims, Scope and Format of the Report

1.2.1 Chapter Outlines

1.3 Research and Analysis Methods

2. Introduction to Companion Diagnostics

2.1 Changing Paradigms of Treatment

2.2 What is Personalised Medicine?

2.3 In Vitro Diagnostics (IVD) and Targeted Therapies: The Core of Personalised Medicine

2.3.1 What are In Vitro Diagnostic (IVD) Tests?

2.3.2 How IVDs Help Provide Personalised Treatment

2.4 Companion Diagnostics: Tools for Personalised Medicine

2.4.1 Theranostics: A Subset of Companion Diagnostics

2.5 Biomarkers to Companion Diagnostics

2.5.1 Genomic Biomarkers

2.5.2 Genomic Biomarkers in Oncology

2.6 Development of Companion Diagnostics

3. The World Companion Diagnostics Market, 2010-2021

3.1 Scope and Limitations

3.2 Total Companion Diagnostics Market was Worth $1.30bn in 2010

3.3 Sales Forecast for Total Companion Diagnostics Market, 2010-2015

3.4 Sales Forecast for Total Companion Diagnostics Market, 2016-2021

3.5 Companion Diagnostics is One of the Fastest Growing Segments in the IVD Market